Tag: chronic pancreatitis cp market analysis

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic pancreatitis (cp) market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Chronic Pancreatitis (CP) Market in 2026, and what figure is it projected to hit by 2030?

The chronic pancreatitis (cp) market size has shown strong growth in recent years. It is expected to grow from $5.23 billion in 2025 to $5.56 billion in 2026, at a compound annual growth rate (CAGR) of 6.4%. The expansion observed in the historical period can be linked to improvements in diagnostic imaging availability, a rise in awareness of pancreatic disorders, the broader application of pain management therapies, the increasing scope of gastroenterology services, and enhanced supportive care options.

The chronic pancreatitis market size is projected for significant expansion in the coming years, anticipated to reach $7.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This growth in the forecast period can be attributed to the increasing development of advanced enzyme formulations, a rising focus on early-stage intervention, the expansion of outpatient treatment models, the growing integration of nutrition-based therapies, and increased investment in pancreatic disease research. Major trends expected during this period involve the increasing use of enzyme replacement therapies, the rising adoption of minimally invasive endoscopic treatments, a growing focus on nutritional management, the expansion of personalized treatment plans, and an enhanced emphasis on early diagnosis.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp

Which Drivers Are Affecting Market Participation In The Chronic Pancreatitis (CP) Market?

The chronic pancreatitis market is projected to expand due to the rising intake of alcohol. Alcohol consumption involves drinking ethanol-containing beverages, typically for social, recreational, or cultural reasons, but excessive intake can result in health issues or dependence. This growing alcohol intake is influenced by factors like greater social acceptance, urbanization, evolving lifestyles, and stress coping mechanisms, particularly prevalent among younger demographics. Alcohol intake contributes to chronic pancreatitis by initiating inflammation and harm to pancreatic cells, resulting in fibrosis, obstructions in the ducts, and eventual long-term dysfunction caused by harmful metabolic byproducts. For instance, regarding the situation in 2025, a 2023 survey cited by the Priory Group (a UK-based provider of mental health, addiction, and specialist education services) determined that 25% of UK individuals aged 18–24 now entirely abstain from alcohol, indicating a significant move towards sobriety among the younger demographic. Consequently, the rising intake of alcohol is fueling the expansion of the chronic pancreatitis market.

What Segment Classifications Make Up The Chronic Pancreatitis (CP) Market?

The chronic pancreatitis (cp) market covered in this report is segmented –

1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Other Treatments

2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral

4) By End User: Hospitals, Homecare, Other End Users

Subsegments:

1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids

2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin

3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein

4) By Other Treatments: Endoscopic Treatment, Surgery

What Upcoming Trends Are Likely To Define The Future Path Of The Chronic Pancreatitis (CP) Market?

Companies active in the chronic pancreatitis market are prioritizing the development of technological advancements, such as enzyme replacement therapy, to address exocrine pancreatic insufficiency (EPI) linked to chronic pancreatitis. This therapy entails patients orally ingesting pancreatic enzymes to aid digestion when pancreatic function is insufficient. As an illustration, in July 2023, First Wave BioPharma Inc, a US-based clinical-stage biopharmaceutical company, disclosed the results from its Phase 2 SPAN clinical trial. This study investigated an enhanced enteric microgranule delivery formulation of adrulipase for managing exocrine pancreatic insufficiency (EPI) in patients with both cystic fibrosis (CF) and chronic pancreatitis. Adrulipase is a recombinant lipase enzyme derived from the Yarrowia lipolytica yeast, delivered as an oral, non-systemic biologic capsule, specifically engineered to break down fat molecules in the digestive tract of EPI patients to enable their absorption as nutrients.

Which Key Players Are Driving Competition In The Chronic Pancreatitis (CP) Market?

Major companies operating in the chronic pancreatitis (cp) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy’s Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report

How Does The Chronic Pancreatitis (CP) Market Perform Across Major Global Regions?

North America was the largest region in the chronic pancreatitis (CP) market in 2025. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Pancreatitis (CP) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp

Browse Through More Reports Similar to the Global Chronic Pancreatitis (CP) Market 2026, By The Business Research Company

Invasive Ductal Carcinoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Pancreatic Cancer Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Exocrine Pancreatic Insufficiency Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Chronic Pancreatitis (CP) Market Be Worth By 2029?

Over recent years, the market size for chronic pancreatitis (cp) has experienced robust growth. The market is projected to expand from $4.91 billion in 2024 to $5.23 billion in 2025, with a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this growth during the historical period include a higher prevalence of alcohol consumption, an increase in smoking cases, genetic predisposition and family history, heightened awareness regarding pancreatic diseases, an uplift in diabetes cases associated with pancreatitis, rising healthcare expenditure, and enhanced accessibility to healthcare services.

There’s anticipation for substantial growth in the Chronic Pancreatitis (cp) market in the coming years with a expected market size of $6.66 billion in 2029, a compound annual growth rate (CAGR) of 6.2%. This future growth is expected to be driven by factors such as the increase in the aging population, a rising demand for enzyme replacement therapies, a growing consciousness about early diagnosis, expansion of medical infrastructure in developing markets and the advancement of novel pain management treatments. Additionally, continuous progress in pancreatitis treatment research and clinical trials are fueling the growth. Key trends for the forecast period are the use of artificial intelligence in diagnostic imaging, the application of minimally invasive surgical procedures, wearable technology for ongoing health tracking, next-generation sequencing for genetic testing, employing machine learning for tracking disease progression, and the innovation of smart diagnostic appliances.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp

What External And Internal Drivers Are Influencing The Chronic Pancreatitis (CP) Market?

The chronic pancreatitis market is predicted to see remarkable growth due to a heightened alcohol intake. The term “alcohol consumption” is defined as the consumption of beverages with ethanol, typically for recreational, social, or cultural events, but it can also cause dependency or health hazards when consumed in large amounts. There is an uptick in alcohol consumption largely due to factors like increased societal acceptance, urbanization, evolving lifestyles, and stress coping mechanisms, particularly among the younger demographic. Consuming alcohol induces chronic pancreatitis as it incites inflammation and impairment to the pancreatic cells, causing fibrosis, obstructions in ducts, and prolonged malfunction due to harmful metabolic waste. For example, a report from Kirin Holdings Company Limited, a beer and beverage firm based in Japan, stated that in December 2023, the total global beer consumption in 2022 increased by approximately 5.4 million kiloliters (equal to nearly 8.5 billion 633ml bottles), a rise from 2021, reaching about 192.1 million kiloliters. This surge of 2.9% was assigned to the relaxation of COVID-19 repercussions, translating to nearly 303.5 billion 633ml bottles. Consequently, the upswing in alcohol consumption is propelling the development of the chronic pancreatitis market.

What Segmentation Insights Are Provided In The Chronic Pancreatitis (CP) Market Research?

The chronic pancreatitis (cp)market covered in this report is segmented –

1) By Treatment: Analgesic; Artificial Digestive Enzyme; Protein Supplements; Steroids; Antibiotics; Other Treatments

2) By Diagnosis: Computed Tomography (CT) Scan; Magnetic Resonance Cholangiopancreatography; Ultrasound Sonography; Other Diagnosis

3) By Route Of Administration: Oral; Parenteral

4) By End User: Hospitals; Homecare; Other End Users

Subsegments:

1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Opioids

2) By Artificial Digestive Enzyme: Pancrelipase; Pancreatin

3) By Protein Supplements: Branched-Chain Amino Acids (BCAA); Whey Protein

4) By Steroids: Prednisone; Dexamethasone

5) By Antibiotics: Ciprofloxacin; Metronidazole

6) By Other Treatments: Endoscopic Treatment; Surgery

Which Notable Trends Are Transforming The Chronic Pancreatitis (CP) Market Outlook?

The primary focus of leading corporations in the chronic pancreatitis market is on the technological advancement of therapies such as enzyme replacement, a new treatment to combat exocrine pancreatic insufficiency (EPI) often linked to chronic pancreatitis. This therapy involves patients orally ingesting pancreatic enzymes to assist in digestion due to inadequate pancreatic function. For example, First Wave BioPharma Inc, a clinical-stage biopharmaceutical company in the US, reported the Phase 2 SPAN clinical trial results in July 2023. The trial investigated an innovative enteric microgranule delivery solution of adrulipase for treating exocrine pancreatic insufficiency (EPI) in patients with chronic pancreatitis and cystic fibrosis (CF). The medication adrulipase, a lipase enzyme derived from the Yarrowia lipolytica yeast, is an oral, non-systemic biological capsule created to break down fat molecules in the EPI patients’ digestive tract to ensure they are absorbed as nutrients.

Who Are The Leading Companies Driving The Chronic Pancreatitis (CP) Market?

Major companies operating in the chronic pancreatitis (CP) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy’s Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Chronic Pancreatitis (CP) Market?

North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp

Browse Through More Reports Similar to the Global Chronic Pancreatitis (CP) Market 2025, By The Business Research Company

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Chronic Lymphocytic Leukemia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lymphocytic-leukemia-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Chronic Pancreatitis (CP) Market Size During 2025–2029?

The chronic pancreatitis (cp) market size has experienced significant expansion over recent years. Forecasts show it will ascend from $4.91 billion in 2024 to $5.23 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.4%. The historical increase can be attributed to several elements, including the rising prevalence of alcohol consumption, an increasing incidence of smoking, genetic predisposition and family history, enhanced awareness of pancreatic diseases, a rise in diabetes cases connected to pancreatitis, increased healthcare spending, and better access to healthcare services.

The market size for chronic pancreatitis (cp) is projected to experience substantial expansion in the coming years. It is anticipated to reach $6.66 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.2%. This growth during the forecast period can be attributed to an expanding elderly population, a heightened demand for enzyme replacement therapies, improved understanding leading to earlier diagnosis, improvements in healthcare infrastructure within developing regions, the introduction of innovative pain management solutions, and a rise in research and clinical studies focused on pancreatitis treatment. Significant trends expected to shape the market over this period encompass the application of artificial intelligence in diagnostic imaging, advancements in minimally invasive surgical methods, the use of wearables for ongoing health surveillance, next-generation sequencing for genetic analysis, the incorporation of machine learning to track disease progression, and the creation of intelligent diagnostic instruments.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp

Which Drivers Are Shaping The Chronic Pancreatitis (CP) Industry’s Market Share?

The growth of the chronic pancreatitis market is anticipated to be driven by the rising consumption of alcohol in the future. Alcohol consumption involves ingesting ethanol-containing drinks, frequently for social, recreational, or cultural reasons, though excessive intake can result in dependency or health hazards. The escalation in alcohol consumption stems from factors like greater social acceptance, urbanization, evolving lifestyles, and methods of stress management, particularly prevalent in younger demographics. Chronic pancreatitis is caused by alcohol consumption, which initiates inflammation and harm to pancreatic cells, subsequently resulting in fibrosis, obstructions in the ducts, and sustained dysfunction attributed to harmful metabolic byproducts. As an illustration, a publication from Kirin Holdings Company Limited, a Japan-based beer and beverage holding company, indicated in December 2023 that worldwide beer consumption in 2022 increased by approximately 5.4 million kiloliters (which equals about 8.5 billion 633ml bottles) from 2021, achieving a total of around 192.1 million kiloliters. This 2.9% rise, translating to roughly 303.5 billion 633ml bottles, was ascribed to the reduced influence of COVID-19. Consequently, the rising intake of alcohol is fueling the expansion of the chronic pancreatitis market.

What Are The Emerging Segments Gaining Attention In The Chronic Pancreatitis (CP) Market?

The chronic pancreatitis (cp)market covered in this report is segmented –

1) By Treatment: Analgesic; Artificial Digestive Enzyme; Protein Supplements; Steroids; Antibiotics; Other Treatments

2) By Diagnosis: Computed Tomography (CT) Scan; Magnetic Resonance Cholangiopancreatography; Ultrasound Sonography; Other Diagnosis

3) By Route Of Administration: Oral; Parenteral

4) By End User: Hospitals; Homecare; Other End Users

Subsegments:

1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Opioids

2) By Artificial Digestive Enzyme: Pancrelipase; Pancreatin

3) By Protein Supplements: Branched-Chain Amino Acids (BCAA); Whey Protein

4) By Steroids: Prednisone; Dexamethasone

5) By Antibiotics: Ciprofloxacin; Metronidazole

6) By Other Treatments: Endoscopic Treatment; Surgery

Which Ongoing Trends Are Expected To Shape The Chronic Pancreatitis (CP) Market Outlook?

Leading companies operating in the chronic pancreatitis market are concentrating on developing technological advancements, notably enzyme replacement therapy, to address exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis. This therapy involves the oral intake of pancreatic enzymes to assist digestion in patients experiencing insufficient pancreatic function. For instance, in July 2023, First Wave BioPharma Inc, a US-based clinical-stage biopharmaceutical company, announced the results from the Phase 2 SPAN clinical trial, which investigated an enhanced enteric microgranule delivery formulation of adrulipase for treating exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis. Adrulipase is a recombinant lipase enzyme derived from the Yarrowia lipolytica yeast, administered as an oral, non-systemic biologic capsule, designed to break up fat molecules in the digestive tract of EPI patients to enable their absorption as nutrients.

Which Industry Leaders Are Driving Innovation Across The Chronic Pancreatitis (CP) Market?

Major companies operating in the chronic pancreatitis (CP) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy’s Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report

What Are The Key Regional Factors Influencing The Chronic Pancreatitis (CP) Market Growth?

North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Pancreatitis (CP) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp

Browse Through More Reports Similar to the Global Chronic Pancreatitis (CP) Market 2025, By The Business Research Company

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Chronic Lymphocytic Leukemia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lymphocytic-leukemia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Chronic Pancreatitis (CP) Market From 2025 To 2029?

The market size for chronic pancreatitis (cp) has significantly expanded in the past few years and is projected to increase from $4.91 billion in 2024 to $5.23 billion in 2025. This growth is expected to maintain a compound annual growth rate (CAGR) of 6.4%. Factors such as growing alcohol intake, escalating instances of smoking, genetic susceptibilities and family histories, growing consciousness about pancreatic conditions, rising diabetes incidences related to pancreatitis, enhanced healthcare expenditure, as well as better access to healthcare services, are responsible for the growth experienced in the previous period.

The market for chronic pancreatitis (cp) is set to experience robust expansion in the following years, with projections suggesting it will reach$6.66 billion by 2029, increasing at a compound annual growth rate (CAGR) of 6.2%. The accelerated growth projected during the forecast period can be linked to various factors including an aging population, increased need for enzyme replacement therapies, heightened consciousness of early diagnosis, healthcare infrastructure development in emerging markets, and the emergence of innovative pain management treatments. Increasing research and clinical trials focused on pancreatitis treatment also contribute to market growth. The forecast period will see trends such as the employment of artificial intelligence in diagnostic imaging, adoption of minimally invasive surgical methods, the use of wearable devices for consistent health monitoring, the application of next-generation sequencing for genetic testing, incorporation of machine learning for disease progression charting, and the creation of intelligent diagnostic tools.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp

Which Primay Drivers Are Accelerating Growth in the Chronic Pancreatitis (CP) Market?

The escalating intake of alcoholic beverages is anticipated to fuel the expansion of the chronic pancreatitis industry. The term alcohol consumption typically implies the use of ethanol-inclusive drinks, typically for leisure, interpersonal, or cultural reasons. However, it can also lead to addiction or health hazards with overindulgence. Factors such as growing social approval, urban development, evolving lifestyles, and stress coping strategies, particularly among younger demographics, promote increased alcohol consumption. Chronic pancreatitis arises from alcohol consumption due to the encouraged inflammation and damage to the pancreas cells, leading to fibrosis, duct blocking, and long-term malfunction from harmful metabolic waste materials. For example, a report by Kirin Holdings Company Limited, a Japanese beer and beverage holding company, in December 2023 shows that the worldwide beer consumption in 2022 spiked by approximately 5.4 million kiloliters (equivalent to nearly 8.5 billion 633ml bottles) from 2021, attaining about 192.1 million kiloliters. This 2.9% surge was credited to the relaxation of COVID-19 consequences, equating to roughly 303.5 billion 633ml bottles. Hence, the rising alcohol consumption trajectories are bolstering the chronic pancreatitis industry’s growth.

Which Primary Segments of the Chronic Pancreatitis (CP) Market Are Driving Growth and Industry Transformations?

The chronic pancreatitis (cp)market covered in this report is segmented –

1) By Treatment: Analgesic; Artificial Digestive Enzyme; Protein Supplements; Steroids; Antibiotics; Other Treatments

2) By Diagnosis: Computed Tomography (CT) Scan; Magnetic Resonance Cholangiopancreatography; Ultrasound Sonography; Other Diagnosis

3) By Route Of Administration: Oral; Parenteral

4) By End User: Hospitals; Homecare; Other End Users

Subsegments:

1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Opioids

2) By Artificial Digestive Enzyme: Pancrelipase; Pancreatin

3) By Protein Supplements: Branched-Chain Amino Acids (BCAA); Whey Protein

4) By Steroids: Prednisone; Dexamethasone

5) By Antibiotics: Ciprofloxacin; Metronidazole

6) By Other Treatments: Endoscopic Treatment; Surgery

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Chronic Pancreatitis (CP) Market?# Market?

North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Chronic Pancreatitis (CP) Industry Dynamics?

Leading entities in the chronic pancreatitis market are prioritizing the development of advanced technologies like enzyme replacement therapy to tackle exocrine pancreatic insufficiency (EPI) linked with chronic pancreatitis. This therapy consists of consuming pancreatic enzymes orally to aid the digestion of patients with deficient pancreatic function. To illustrate, First Wave BioPharma Inc, a US-based biopharmaceutical establishment engaged in clinical-stage drug development, disclosed in July 2023 the outcome of the Phase 2 SPAN clinical trial. This trial analyzed an improved enteric microgranule delivery formulation of adrulipase for treating EPI in patients suffering from cystic fibrosis (CF) and chronic pancreatitis. Adrulipase, an oral, non-systemic biologic capsule, is a recombinant lipase enzyme sourced from the Yarrowia lipolytica yeast, purposed to decompose fat molecules in EPI patients’ digestive tract for nutrient absorption.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report

What Parameters Are Used to Define the Chronic Pancreatitis (CP) Market?

Chronic pancreatitis (CP) is a long-lasting, progressive inflammatory condition of the pancreas that causes permanent damage to its structure and function. The disease is marked by persistent inflammation, fibrosis (scarring), and the eventual deterioration of the pancreas’s ability to produce digestive enzymes and hormones such as insulin.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21146

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Chronic Pancreatitis (CP) Market?

In recent times, there has been a robust growth in the market size of Chronic Pancreatitis (CP). The market, which stood at $4.91 billion in 2024, is projected to expand to $5.25 billion in 2025, resulting in a Compound Annual Growth Rate (CAGR) of 6.7%. Several factors can be credited for the market’s growth during the historic period. They include the growing prevalence of alcohol consumption, an increase in smoking cases, genetic factors and family history, increased awareness about pancreatic diseases, a surge in diabetes cases related to pancreatitis, augmented healthcare expenditure, and enhanced access to healthcare services.

What Growth Rate Is Forecasted for the Chronic Pancreatitis (CP) Market by 2029?

In the upcoming years, the chronic pancreatitis (CP) market is predicted to experience robust growth. The projection is set at a compound annual growth rate (CAGR) of 6.4%, taking the market value up to $6.72 billion by 2029. The factors contributing to the growth in the predicted period could be the increasing aged population, a rise in the necessity of enzyme replacement therapies, the growth in awareness of early diagnosis, health infrastructure growth in emerging markets, the development of new pain management therapies, and an increase in research and clinical trials for treating pancreatitis. Major upcoming trends for the forecast period include the application of artificial intelligence in diagnostic imaging, implementation of minimally invasive surgical techniques, the usage of wearables for constant health monitoring, next-generation sequencing for genetic testing, incorporation of machine learning for tracking disease progression and the creation of smart diagnostic instruments.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp

Which Key Companies Are Shaping the Future of the Chronic Pancreatitis (CP) Market?

Major companies operating in the chronic pancreatitis (CP) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy’s Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech

Which Factors Are Driving Demand in the Chronic Pancreatitis (CP) Industry?

The chronic pancreatitis market is expected to surge due to the rising consumption of alcohol. This use is described as the imbibing of beverages with ethanol, frequently for pleasure, social interaction, or culture. Nevertheless, alcohol dependency or health problems can ensue from overconsumption. Growth in alcohol consumption is spurred by factors such as increased societal acceptance, urbanization, evolving living habits, and stress coping methodologies, predominantly among younger demographics. Alcohol-induced pancreatitis is caused by inflammation and injury to pancreatic cells, leading to fibrosis, blocked ducts, and lasting dysfunction from harmful metabolic waste products. For example, data published by Kirin Holdings Company Limited, a Japanese beer and beverage holding company, in December 2023 indicated a rise in total global beer consumption by around 5.4 million kiloliters (equivalent to around 8.5 billion 633ml bottles) in 2022 compared to 2021, reaching around 192.1 million kiloliters. This rise of approximately 2.9% was credited to the relaxation of COVID-19 effects, accounting for nearly 303.5 billion 633ml bottles. Consequently, the escalating consumption of alcohol is fuelling the chronic pancreatitis market’s expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp

How Is the Chronic Pancreatitis (CP) Market Segmented by Several Divisions?

The chronic pancreatitis (CP) market covered in this report is segmented –

1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, Other Treatments

2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral

4) By End User: Hospitals, Homecare, Other End Users

Subsegments:

1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids

2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin

3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein

4) By Steroids: Prednisone, Dexamethasone

5) By Antibiotics: Ciprofloxacin, Metronidazole

6) By Other Treatments: Endoscopic Treatment, Surgery

What are the Emerging Market Trends Driving the Growth of the Chronic Pancreatitis (CP) Industry?

Key players in the chronic pancreatitis market are putting their efforts into creating technological breakthroughs such as enzyme replacement therapy to treat exocrine pancreatic insufficiency (EPI), a condition linked with chronic pancreatitis. This treatment method involves patients with inadequate pancreatic function consuming oral pancreatic enzymes to support digestion. For instance, in July 2023, clinical-stage biopharmaceutical firm based in the US, First Wave BioPharma Inc, revealed the results from the Phase 2 SPAN clinical test. The trial was on an improved enteric microgranule delivery formulation of adrulipase aimed at treating exocrine pancreatic insufficiency (EPI) in patients with chronic pancreatitis and cystic fibrosis (CF). Adrulipase is an oral, non-systemic biologic capsule, which is a recombinant lipase enzyme originating from the Yarrowia lipolytica yeast. Its purpose is to disintegrate fat molecules in the digestive system of EPI patients so that it can be absorbed as nutrients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report

Which Regions Are Driving Growth in the Chronic Pancreatitis (CP) Market?

North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21146

This Report Delivers Insight On:

1. How big is the chronic pancreatitis (cp) market, and how is it changing globally?

2. Who are the major companies in the chronic pancreatitis (cp) market, and how are they performing?

3. What are the key opportunities and risks in the chronic pancreatitis (cp) market right now?

4. Which products or customer segments are growing the most in the chronic pancreatitis (cp) market?

5. What factors are helping or slowing down the growth of the chronic pancreatitis (cp) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Are the Key Milestones in the Chronic Pancreatitis (CP) Market’s Growth Trajectory From 2025 To 2034?

In recent times, the market for Chronic Pancreatitis (CP) has witnessed notable growth. Projected to scale from a valuation of $4.91 billion in 2024 to about $5.25 billion in 2025, it carries an anticipated compound annual growth rate (CAGR) of 6.7%. Drivers for growth in the past period have included increasing levels of alcohol consumption, a higher incidence of smoking, genetic factors and family history, enhanced awareness about pancreatic diseases, a rise in the number of diabetes cases connected to pancreatitis, escalating healthcare expenditure, and improved accessibility to healthcare services.

In the coming years, the market for chronic pancreatitis (CP) is projected to observe substantial growth, expanding to $6.72 billion in 2029 with a compound annual growth rate (CAGR) of 6.4%. The projected growth during this forecast period can be linked to factors like the growing elderly population, heightened demand for enzyme replacement treatments, increasing comprehension of the importance of early detection, healthcare infrastructure development in up-and-coming markets, and the invention of new therapeutic methods for pain management. Furthermore, rising research and clinical investigations aimed at pancreatitis cure contributes to the growth. Major upcoming trends during the forecast period include incorporation of artificial intelligence in diagnostic imaging, less invasive surgical procedures, wearable devices for ongoing health tracking, advancements in genetic testing through next-generation sequencing, machine learning application for tracking disease progression, and the creation of smart diagnostic instruments.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp

What Are the Core Growth Drivers Propelling the Chronic Pancreatitis (CP) Market Forward?

The chronic pancreatitis market is expected to expand due to the rising prevalence of alcohol consumption. Drinking alcohol involves the consumption of ethanol-based beverages, most often for leisurely, social, or cultural reasons, but can also result in addiction or health risks if indulged in excessively. Multiple factors, including growing social acceptance, urbanization, lifestyle modifications, and stress coping mechanisms, particularly among younger demographics, fuel the rise in alcohol consumption. Chronic pancreatitis is induced by alcohol consumption as it initiates inflammation and harm to the pancreatic cells, resulting in fibrosis, duct obstructions, and long-term malfunctions due to harmful metabolic byproducts. For example, in December 2023, as per data published by Kirin Holdings Company Limited, a Japanese beer and beverage holding firm, the total worldwide beer consumption in 2022 increased by approximately 5.4 million kiloliters (equal to roughly 8.5 billion 633ml bottles) compared to 2021, reaching approximately 192.1 million kiloliters. This 2.9% increase is credited to the mitigation of the impact of COVID-19, totaling to approximately 303.5 billion 633ml bottles. Hence, the rise in alcohol consumption is propelling the growth of the chronic pancreatitis market.

What Segment Types Define the Chronic Pancreatitis (CP) Market Structure?

The chronic pancreatitis (CP) market covered in this report is segmented –

1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, Other Treatments

2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral

4) By End User: Hospitals, Homecare, Other End Users

Subsegments:

1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids

2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin

3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein

4) By Steroids: Prednisone, Dexamethasone

5) By Antibiotics: Ciprofloxacin, Metronidazole

6) By Other Treatments: Endoscopic Treatment, Surgery

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Chronic Pancreatitis (CP) Market?

North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theChronic Pancreatitis (CP) Industry Evolution?

Key players in the chronic pancreatitis market are making strides in technological evolution, particularly in enzyme replacement therapy, aimed at managing exocrine pancreatic insufficiency (EPI) related to chronic pancreatitis. This therapy involves the consumption of oral pancreatic enzymes that aid in digestion for patients whose pancreatic functionality is compromised. For example, results were revealed from the Phase 2 SPAN clinical trial by First Wave BioPharma Inc, a US-based clinical-stage biopharmaceutical company, in July 2023. The trial investigated adrulipase, an enhanced enteric microgranule delivery formulation for treating EPI in patients suffering from cystic fibrosis (CF) and chronic pancreatitis. Adrulipase is a recombinant lipase enzyme procured from the Yarrowia lipolytica yeast and is administered as an oral non-systemic biologic capsule. It is designed to disintegrate fat molecules in the EPI patient’s digestive tract, enabling their absorption as nutrients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report

What Is the Definition of the Chronic Pancreatitis (CP) Market?

Chronic pancreatitis (CP) is a long-lasting, progressive inflammatory condition of the pancreas that causes permanent damage to its structure and function. The disease is marked by persistent inflammation, fibrosis (scarring), and the eventual deterioration of the pancreas’s ability to produce digestive enzymes and hormones such as insulin.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21146

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model